Logo image of TXG

10X GENOMICS INC-CLASS A (TXG) Stock Fundamental Analysis

USA - NASDAQ:TXG - US88025U1097 - Common Stock

11.72 USD
-0.23 (-1.92%)
Last: 9/26/2025, 7:10:07 PM
11.72 USD
0 (0%)
After Hours: 9/26/2025, 7:10:07 PM
Fundamental Rating

4

Overall TXG gets a fundamental rating of 4 out of 10. We evaluated TXG against 56 industry peers in the Life Sciences Tools & Services industry. While TXG has a great health rating, there are worries on its profitability. TXG is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

TXG had negative earnings in the past year.
TXG had a positive operating cash flow in the past year.
In the past 5 years TXG always reported negative net income.
TXG had negative operating cash flow in 4 of the past 5 years.
TXG Yearly Net Income VS EBIT VS OCF VS FCFTXG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M -400M -500M

1.2 Ratios

Looking at the Return On Assets, with a value of -8.63%, TXG is in line with its industry, outperforming 50.00% of the companies in the same industry.
TXG has a Return On Equity (-10.94%) which is in line with its industry peers.
Industry RankSector Rank
ROA -8.63%
ROE -10.94%
ROIC N/A
ROA(3y)-20.81%
ROA(5y)-25.31%
ROE(3y)-26.91%
ROE(5y)-32.26%
ROIC(3y)N/A
ROIC(5y)N/A
TXG Yearly ROA, ROE, ROICTXG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

The Gross Margin of TXG (69.50%) is better than 94.64% of its industry peers.
In the last couple of years the Gross Margin of TXG has declined.
TXG does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.5%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.17%
GM growth 5Y-2.02%
TXG Yearly Profit, Operating, Gross MarginsTXG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

8

2. Health

2.1 Basic Checks

TXG does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TXG has more shares outstanding
Compared to 5 years ago, TXG has more shares outstanding
There is no outstanding debt for TXG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TXG Yearly Shares OutstandingTXG Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
TXG Yearly Total Debt VS Total AssetsTXG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

TXG has an Altman-Z score of 3.04. This indicates that TXG is financially healthy and has little risk of bankruptcy at the moment.
TXG's Altman-Z score of 3.04 is fine compared to the rest of the industry. TXG outperforms 66.07% of its industry peers.
TXG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 3.04
ROIC/WACCN/A
WACC10.42%
TXG Yearly LT Debt VS Equity VS FCFTXG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

TXG has a Current Ratio of 5.84. This indicates that TXG is financially healthy and has no problem in meeting its short term obligations.
TXG's Current ratio of 5.84 is fine compared to the rest of the industry. TXG outperforms 78.57% of its industry peers.
A Quick Ratio of 5.23 indicates that TXG has no problem at all paying its short term obligations.
The Quick ratio of TXG (5.23) is better than 78.57% of its industry peers.
Industry RankSector Rank
Current Ratio 5.84
Quick Ratio 5.23
TXG Yearly Current Assets VS Current LiabilitesTXG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 61.39% over the past year.
TXG shows a small growth in Revenue. In the last year, the Revenue has grown by 2.02%.
TXG shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.96% yearly.
EPS 1Y (TTM)61.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%187.5%
Revenue 1Y (TTM)2.02%
Revenue growth 3Y7.58%
Revenue growth 5Y19.96%
Sales Q2Q%12.93%

3.2 Future

The Earnings Per Share is expected to grow by 15.77% on average over the next years. This is quite good.
TXG is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.94% yearly.
EPS Next Y55.3%
EPS Next 2Y17.03%
EPS Next 3Y16.78%
EPS Next 5Y15.77%
Revenue Next Year2.07%
Revenue Next 2Y0.26%
Revenue Next 3Y3.7%
Revenue Next 5Y3.94%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
TXG Yearly Revenue VS EstimatesTXG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
TXG Yearly EPS VS EstimatesTXG Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2 -3 -4 -5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TXG. In the last year negative earnings were reported.
Also next year TXG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TXG Price Earnings VS Forward Price EarningsTXG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

TXG's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. TXG is cheaper than 76.79% of the companies in the same industry.
Industry RankSector Rank
P/FCF 25.65
EV/EBITDA N/A
TXG Per share dataTXG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

TXG's earnings are expected to grow with 16.78% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.03%
EPS Next 3Y16.78%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TXG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

10X GENOMICS INC-CLASS A

NASDAQ:TXG (9/26/2025, 7:10:07 PM)

After market: 11.72 0 (0%)

11.72

-0.23 (-1.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)10-27 2025-10-27/amc
Inst Owners104.25%
Inst Owner Change7.3%
Ins Owners1.65%
Ins Owner Change0.92%
Market Cap1.46B
Analysts73.64
Price Target15.3 (30.55%)
Short Float %12.24%
Short Ratio4.73
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)99.48%
Min EPS beat(2)24.36%
Max EPS beat(2)174.61%
EPS beat(4)3
Avg EPS beat(4)44.4%
Min EPS beat(4)-34.43%
Max EPS beat(4)174.61%
EPS beat(8)5
Avg EPS beat(8)16.13%
EPS beat(12)7
Avg EPS beat(12)12.99%
EPS beat(16)8
Avg EPS beat(16)2.08%
Revenue beat(2)2
Avg Revenue beat(2)19.28%
Min Revenue beat(2)15.77%
Max Revenue beat(2)22.78%
Revenue beat(4)3
Avg Revenue beat(4)8.93%
Min Revenue beat(4)-5.35%
Max Revenue beat(4)22.78%
Revenue beat(8)5
Avg Revenue beat(8)4.38%
Revenue beat(12)9
Avg Revenue beat(12)3.89%
Revenue beat(16)11
Avg Revenue beat(16)2.52%
PT rev (1m)10.8%
PT rev (3m)14.03%
EPS NQ rev (1m)-2.16%
EPS NQ rev (3m)0.22%
EPS NY rev (1m)0%
EPS NY rev (3m)44.18%
Revenue NQ rev (1m)-0.1%
Revenue NQ rev (3m)-0.74%
Revenue NY rev (1m)0.4%
Revenue NY rev (3m)4.79%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.26
P/FCF 25.65
P/OCF 21.79
P/B 1.89
P/tB 1.93
EV/EBITDA N/A
EPS(TTM)-0.78
EYN/A
EPS(NY)-0.96
Fwd EYN/A
FCF(TTM)0.46
FCFY3.9%
OCF(TTM)0.54
OCFY4.59%
SpS5.18
BVpS6.21
TBVpS6.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.63%
ROE -10.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.5%
FCFM 8.83%
ROA(3y)-20.81%
ROA(5y)-25.31%
ROE(3y)-26.91%
ROE(5y)-32.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.17%
GM growth 5Y-2.02%
F-Score6
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 22.39%
Cap/Sales 1.56%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.84
Quick Ratio 5.23
Altman-Z 3.04
F-Score6
WACC10.42%
ROIC/WACCN/A
Cap/Depr(3y)221.05%
Cap/Depr(5y)283.34%
Cap/Sales(3y)11.9%
Cap/Sales(5y)13.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)61.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%187.5%
EPS Next Y55.3%
EPS Next 2Y17.03%
EPS Next 3Y16.78%
EPS Next 5Y15.77%
Revenue 1Y (TTM)2.02%
Revenue growth 3Y7.58%
Revenue growth 5Y19.96%
Sales Q2Q%12.93%
Revenue Next Year2.07%
Revenue Next 2Y0.26%
Revenue Next 3Y3.7%
Revenue Next 5Y3.94%
EBIT growth 1Y33.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year28.23%
EBIT Next 3Y19.88%
EBIT Next 5Y15.24%
FCF growth 1Y148.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y682.7%
OCF growth 3YN/A
OCF growth 5Y-28.08%